Yeung Ming-Wai, Wong Grace Lai-Hung, Choi Kai Chow, Luk Andrea On-Yan, Kwok Raymond, Shu Sally She-Ting, Chan Anthony Wing-Hung, Lau Eric Siu Him, Ma Ronald Ching Wan, Chan Henry Lik-Yuen, Chan Juliana Chung-Ngor, Wong Vincent Wai-Sun, Kong Alice Pik-Shan
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong; Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong; State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
J Hepatol. 2017 Oct 6. doi: 10.1016/j.jhep.2017.09.020.
BACKGROUND & AIMS: Increasing evidence suggests that non-alcoholic fatty liver disease (NAFLD) may be an independent risk factor for chronic kidney disease (CKD). Given the high prevalence of NAFLD among patients with diabetes who are also at risk of CKD, we aimed to investigate the association between NAFLD and albuminuria, a marker commonly found in diabetic nephropathy.
This study included a cohort of Chinese patients with type 2 diabetes from the Hong Kong Diabetes Registry recruited between March 2013 and May 2014. Liver stiffness measurement (LSM), with probe-specific cut-offs, was used to detect advanced liver fibrosis. While controlled attenuation parameter (CAP) was used to assess liver steatosis using transient elastography.
A total of 1,763 Chinese patients with type 2 diabetes were recruited in this analysis. The mean (standard deviation) age and duration of diabetes were 60.7 (11.5) years and 10.8 (8.5) years, respectively. The prevalence of albuminuria was higher in diabetic patients with liver steatosis and those with advanced fibrosis (no NAFLD vs. liver steatosis vs. advanced fibrosis: 41.4% vs. 46.2% vs. 64.2%, p <0.001). After adjustment for potential confounders including glycated hemoglobin, hypertension and body mass index, advanced fibrosis, but not liver steatosis, was associated with increased risk of albuminuria (odds ratio [OR] 1.52; 95% confidence interval [CI] 1.02-2.28; p = 0.039) in patients with eGFR ≥60 ml/min/1.73 m. The odds of albuminuria increased with greater severity of liver fibrosis in a dose dependent manner, with the highest odds observed in patients with LSM scores ≥11.5 kPa assessed by M probe or ≥11.0 kPa assessed by XL probe (adjusted OR 1.53; 95% CI 1.07-2.20; p = 0.021).
Advanced liver fibrosis, but not steatosis, is independently associated with albuminuria in Chinese patients with type 2 diabetes. Attention should be paid to liver fibrosis in patients with obesity and type 2 diabetes complicated with albuminuria.
In this study, we assessed the link between non-alcoholic fatty liver disease (NAFLD) and albuminuria in a cohort of 1,763 Chinese patients with type 2 diabetes. This study shows that advanced liver fibrosis, a severe form of NAFLD, was independently associated with increased risk of albuminuria. The risk of albuminuria increased with greater severity of liver fibrosis.
越来越多的证据表明,非酒精性脂肪性肝病(NAFLD)可能是慢性肾脏病(CKD)的独立危险因素。鉴于NAFLD在同样有CKD风险的糖尿病患者中患病率很高,我们旨在研究NAFLD与蛋白尿之间的关联,蛋白尿是糖尿病肾病中常见的一个指标。
本研究纳入了2013年3月至2014年5月从香港糖尿病登记处招募的一组中国2型糖尿病患者。采用具有特定探头截断值的肝脏硬度测量(LSM)来检测晚期肝纤维化。同时,使用受控衰减参数(CAP)通过瞬时弹性成像评估肝脏脂肪变性。
本分析共纳入1763例中国2型糖尿病患者。糖尿病的平均(标准差)年龄和病程分别为60.7(11.5)岁和10.8(8.5)年。有肝脏脂肪变性和晚期纤维化的糖尿病患者蛋白尿患病率更高(无NAFLD vs. 肝脏脂肪变性 vs. 晚期纤维化:41.4% vs. 46.2% vs. 64.2%,p<0.001)。在调整了包括糖化血红蛋白、高血压和体重指数等潜在混杂因素后,在估算肾小球滤过率(eGFR)≥60 ml/min/1.73 m²的患者中,晚期纤维化而非肝脏脂肪变性与蛋白尿风险增加相关(比值比[OR] 1.52;95%置信区间[CI] 1.02 - 2.28;p = 0.039)。蛋白尿的几率随着肝纤维化严重程度的增加呈剂量依赖性增加,在使用M探头评估LSM评分≥11.5 kPa或使用XL探头评估≥11.0 kPa的患者中观察到最高几率(调整后OR 1.53;95% CI 1.07 - 2.20;p = 0.021)。
在患有2型糖尿病的中国患者中,晚期肝纤维化而非脂肪变性与蛋白尿独立相关。对于肥胖且2型糖尿病合并蛋白尿的患者,应关注肝纤维化。
在本研究中,我们评估了1763例中国2型糖尿病患者队列中非酒精性脂肪性肝病(NAFLD)与蛋白尿之间的联系。这项研究表明,晚期肝纤维化作为NAFLD的一种严重形式,与蛋白尿风险增加独立相关。蛋白尿的风险随着肝纤维化严重程度的增加而增加。